Search results
Results From The WOW.Com Content Network
Technetium (99m Tc) sestamibi is a lipophilic cation which, when injected intravenously into a patient, distributes in the myocardium proportionally to the myocardial blood flow. Single photon emission computed tomography imaging of the heart is performed using a gamma camera to detect the gamma rays emitted by the technetium-99m as it decays.
Technetium-99m (Tc-99m) can be readily detected in the body by medical equipment because it emits 140.5 keV gamma rays (these are about the same wavelength as emitted by conventional X-ray diagnostic equipment), and its half-life for gamma emission is six hours (meaning 94% of it decays to 99 Tc in 24 hours). Besides, it emits virtually no beta ...
Radioactive technetium-99m is combined with DMSA and injected into a patient, followed by imaging with a gamma camera after 2-3 hours. [1] A DMSA scan is usually static imaging, while other radiotracers like DTPA and MAG3 are usually used for dynamic imaging to assess renal excretion. [2] The major clinical indications for this investigation are
The most common isotope used in diagnostic scans is Technetium-99m, used in approximately 85% of all nuclear medicine diagnostic scans worldwide. It is used for diagnoses involving a large range of body parts and diseases such as cancers and neurological problems. [1]
Technetium (99m Tc) tetrofosmin is a drug used in nuclear medicine cardiac imaging.It is sold under the brand name Myoview (GE Healthcare).The radioisotope, technetium-99m, is chelated by two 1,2-bis[di-(2-ethoxyethyl)phosphino]ethane ligands which belong to the group of diphosphines and which are referred to as tetrofosmin.
The test was first introduced in 1956, using iodine-131 diodrast. [25] [26] Later developments included iodine-131, and then iodine-123, labelled ortho-Iodohippuric acid (OIH, marketed as Hippuran). [27] [28] 99m Tc-MAG3 has replaced 131 I-OIH because of better quality imaging regardless of the level of kidney function, [29] and lower radiation ...
Technetium (99m Tc) mertiatide is a radiopharmaceutical medication used in nuclear medicine to image the kidneys. [1] It is a renal imaging agent that is given by intravenous injection. [1] It was approved for medical use in the United States in June 1990. [2]
The metastable technetium-99m (99m Tc) is a short-lived (half-life about 6 hours) nuclear isomer used in nuclear medicine, produced from molybdenum-99. It decays by isomeric transition to technetium-99, a desirable characteristic, since the very long half-life and type of decay of technetium-99 imposes little further radiation burden on the body.